The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The cyclin-dependent kinases pathway as a target for prostate cancer treatment: rationale and future perspectives
Authors
Keywords
Castration resistance, Castration-sensitive, Cyclin D1, CDK signaling, Randomized controlled trial, Drug development
Journal
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume 157, Issue -, Pages 103199
Publisher
Elsevier BV
Online
2020-12-13
DOI
10.1016/j.critrevonc.2020.103199
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- ECCO Essential Requirements for Quality Cancer Care: Prostate cancer
- (2020) Maurizio Brausi et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Pharmacodynamics effects of CDK4/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised Prostate cancer)
- (2020) Tahlia Scheinberg et al. BMJ Open
- Systematic Characterization of Recurrent Genomic Alterations in Cyclin-Dependent Kinases Reveals Potential Therapeutic Strategies for Cancer Treatment
- (2020) Weiwei Shan et al. Cell Reports
- Cyclin-dependent kinase 4/6 inhibitors for cancer therapy: a patent review (2015 – 2019)
- (2020) Peng-Fei Wang et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Plasma Androgen Receptor in Prostate Cancer
- (2019) Vincenza Conteduca et al. Cancers
- Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial
- (2018) L Malorni et al. ANNALS OF ONCOLOGY
- Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial
- (2018) H S Rugo et al. ANNALS OF ONCOLOGY
- Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).
- (2018) Phillip Lee Palmbos et al. JOURNAL OF CLINICAL ONCOLOGY
- Abemaciclib: a CDK4/6 inhibitor for the treatment of HR+/HER2– advanced breast cancer
- (2018) Silvia Paola Corona et al. Drug Design Development and Therapy
- Plasma DNA Analysis in Prostate Cancer: Opportunities for Improving Clinical Management
- (2018) Anjui Wu et al. CLINICAL CHEMISTRY
- Randomized Phase II Study Evaluating Palbociclib in Addition to Letrozole as Neoadjuvant Therapy in Estrogen Receptor–Positive Early Breast Cancer: PALLET Trial
- (2018) Stephen Johnston et al. JOURNAL OF CLINICAL ONCOLOGY
- Circulating tumor DNA in advanced prostate cancer: transitioning from discovery to a clinically implemented test
- (2018) Enrique González-Billalabeitia et al. PROSTATE CANCER AND PROSTATIC DISEASES
- CDK 4/6 Inhibitors as Single Agent in Advanced Solid Tumors
- (2018) Francesco Schettini et al. Frontiers in Oncology
- EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer
- (2017) Philip Cornford et al. EUROPEAN UROLOGY
- MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
- (2017) George W. Sledge et al. JOURNAL OF CLINICAL ONCOLOGY
- MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer
- (2017) Matthew P. Goetz et al. JOURNAL OF CLINICAL ONCOLOGY
- CDK4/6 inhibition triggers anti-tumour immunity
- (2017) Shom Goel et al. NATURE
- Biological specificity of CDK4/6 inhibitors: dose response relationship, in vivo signaling, and composite response signature
- (2017) Erik S. Knudsen et al. Oncotarget
- Ribociclib plus letrozole in early breast cancer: A presurgical, window-of-opportunity study
- (2016) G. Curigliano et al. BREAST
- Targeting CDK4/6 in patients with cancer
- (2016) Erika Hamilton et al. CANCER TREATMENT REVIEWS
- Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
- (2016) Massimo Cristofanilli et al. LANCET ONCOLOGY
- Spectrum and Degree of CDK Drug Interactions Predicts Clinical Performance
- (2016) P. Chen et al. MOLECULAR CANCER THERAPEUTICS
- Ribociclib as First-Line Therapy for HR-Positive, Advanced Breast Cancer
- (2016) Gabriel N. Hortobagyi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Palbociclib and Letrozole in Advanced Breast Cancer
- (2016) Richard S. Finn et al. NEW ENGLAND JOURNAL OF MEDICINE
- The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
- (2015) Richard S Finn et al. LANCET ONCOLOGY
- Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer
- (2015) Nicholas C. Turner et al. NEW ENGLAND JOURNAL OF MEDICINE
- DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
- (2015) Joaquin Mateo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Androgen receptor antagonists for prostate cancer therapy
- (2014) Christine Helsen et al. ENDOCRINE-RELATED CANCER
- Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma
- (2013) J. Rader et al. CLINICAL CANCER RESEARCH
- Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
- (2013) C. Parker et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting cell cycle and hormone receptor pathways in cancer
- (2013) C E S Comstock et al. ONCOGENE
- Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
- (2012) Howard I. Scher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Early G1 Cyclin-Dependent Kinases as Prognostic Markers and Potential Therapeutic Targets in Esophageal Adenocarcinoma
- (2011) A. Ismail et al. CLINICAL CANCER RESEARCH
- Phase I, Dose-Escalation Trial of the Oral Cyclin-Dependent Kinase 4/6 Inhibitor PD 0332991, Administered Using a 21-Day Schedule in Patients with Advanced Cancer
- (2011) K. T. Flaherty et al. CLINICAL CANCER RESEARCH
- Therapeutically activating RB: reestablishing cell cycle control in endocrine therapy-resistant breast cancer
- (2011) C. Thangavel et al. ENDOCRINE-RELATED CANCER
- Abiraterone and Increased Survival in Metastatic Prostate Cancer
- (2011) Johann S. de Bono et al. NEW ENGLAND JOURNAL OF MEDICINE
- A bioinformatical and functional approach to identify novel strategies for chemoprevention of colorectal cancer
- (2011) D M Heijink et al. ONCOGENE
- ER -Dependent E2F Transcription Can Mediate Resistance to Estrogen Deprivation in Human Breast Cancer
- (2011) T. W. Miller et al. Cancer Discovery
- A Synthetic Lethal Interaction between K-Ras Oncogenes and Cdk4 Unveils a Therapeutic Strategy for Non-small Cell Lung Carcinoma
- (2010) Marta Puyol et al. CANCER CELL
- Pharmacologic Inhibition of Cyclin-Dependent Kinases 4 and 6 Arrests the Growth of Glioblastoma Multiforme Intracranial Xenografts
- (2010) K. Michaud et al. CANCER RESEARCH
- Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial
- (2010) Johann Sebastian de Bono et al. LANCET
- Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
- (2010) W. R. Wiedemeyer et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Treatment of Growing Teratoma Syndrome
- (2009) David J. Vaughn et al. NEW ENGLAND JOURNAL OF MEDICINE
- A Novel Therapeutic Combination Using PD 0332991 and Bortezomib: Study in the 5T33MM Myeloma Model
- (2008) E. Menu et al. CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started